B A C K G R O U N D
Cough is the most common symptom presenting to general practitioners (Britt 2002; Cherry 2003) and causes significant anxiety to parents (Cornford 1993) . Worldwide the desire to reduce the impact of the symptom of cough is reflected in the billions of dollars spent on over the counter cough and cold medications. Non-specific cough has been defined as non-productive cough in the absence of identifiable respiratory disease or known aetiology (Chang 2001) . While some children with chronic non-specific cough have asthma, the majority do not (McKenzie 1994; Chang 1999) . In adults, chronic cough is defined as cough of over 8 weeks duration but the definition commonly accepted in children is that of over 3-4 weeks, based on the known differences between paediatric and adults cough (Chang 2005b).
The leukotriene pathway is reported to be involved in the sensory (neurogenic) pathway (Ishikawa 1996) which is a key mechanism thought to be involved in the pathogenesis of chronic cough (Mazzone 2004; Widdicombe 1995) . Although leukotriene receptor antagonists (LTRA) are now primarily used for asthma, they have also been shown to reduce respiratory symptoms associated with post respiratory syncytial virus (RSV) infection (Bisgaard 2003) . The influence of LTRA in post RSV bronchiolitis is likely through the effect of LTRA on the neurogenic pathway, as demonstrated in animal work (Wedde-Beer 2002) . While post RSV bronchiolitis symptoms do not constitute non-specific cough, a similar mechanism involving the neurogenic pathway maybe involved in the pathophysiology of chronic non-specific cough. Thus it is biologically plausible that LTRA may be beneficial in non-specific cough (separate to its anti-asthma properties) through its action on the neurogenic pathway. However like all medications, use of LTRAs may cause adverse events. A systematic review of the benefits (or otherwise) of LTRA on chronic non-specific cough would thus be useful to help guide clinical practice.
O B J E C T I V E S
To evaluate the effectiveness of LTRA in treating children with prolonged non-specific cough.
M E T H O D S Criteria for considering studies for this review

Types of studies
All randomised controlled trials comparing LTRA with a placebo medication with cough as an outcome, where cough is not primarily related to an underlying respiratory disorder such as cystic fibrosis, asthma, suppurative lung disease etc.
Types of participants
Children with chronic (>4 weeks) non-specific cough (dry and non-productive cough without any other respiratory symptom, sign or systemic illness). Exclusion criteria: cough related to mycoplasma, pertussis and chlamydia, presence of underlying cardio-respiratory condition, current or recurrent wheeze (>2 episodes), presence of other respiratory symptoms (productive or wet cough (Chang 2005a), haemoptysis, dyspnoea), presence of other respiratory signs (clubbing, chest wall deformity, respiratory noises such as wheeze on auscultation and other adventitious sounds), presence of any sign of systemic illness (failure to thrive, aspiration, neurological or developmental abnormality), presence of lung function abnormality.
Types of interventions
All randomised controlled comparisons of any type of LTRA. Trials only comparing two or more medications without a placebo comparison group will not be included. Trials that included the use of other medications or interventions were to be included if all participants had equal access to such medications or interventions.
Types of outcome measures
Primary outcomes
Proportions of participants who were not cured or not substantially improved at follow up (clinical failure).
Secondary outcomes
1. Proportions of participants who were not cured at follow up, 2. Proportions of participants who not substantially improved at follow up, 3. Mean difference in cough indices (cough diary, cough frequency, cough scores), 4. Proportions experiencing adverse effects of the intervention, (e.g. seizures, school performance etc), 5. Proportions experiencing complications e.g. requirement for medication change, etc. The proportions of participants who failed to improve on treatment and the mean clinical improvement were to be determined using the following hierarchy of assessment measures (i.e. where two or more assessment measures are reported in the same study, the outcome measure that is listed first in the hierarchy would have been used). i) Objective measurements of cough indices (cough frequency, cough receptor sensitivity). ii) Symptomatic (Quality of life, Likert scale, visual analogue scale, level of interference of cough, cough diary) -assessed by the patient (adult or child) iii) Symptomatic (Quality of life, Likert scale, visual analogue scale, level of interference of cough, cough diary) -assessed by the parents/carers. iv) Symptomatic (Likert scale, visual analogue scale, level of interference of cough, cough diary) -assessed by clinicians. v) Relevant airway markers consistent with inflammation.
Search methods for identification of studies
The latest searches were carried out in October 2010.
Electronic searches
The following topic search strategy was used to identify the relevant randomised controlled trials listed on the electronic databases: "cough" OR "bronchitis", all as (textword) or (MeSH ) AND "leukotriene receptor" OR "leukotrienes" OR "montelukast" OR "LTRA" OR "zafirlukast", OR "pranlukast"; all as (textword) or (MeSH) (see Appendix 1) Trials were identified from the following sources:
1 
Data collection and analysis
Selection of studies
From the title, abstract, or descriptors, two reviewers (AC, DW) independently reviewed literature searches to identify potentially relevant trials for full review. Searches of bibliographies and texts were conducted to identify additional studies. From the full text using specific criteria, reviewers independently selected trials for inclusion. Agreement would have been measured using kappa statistics. Disagreement would have been resolved by third party adjudication (JA).
Data extraction and management
Trials that satisfied the inclusion criteria were reviewed and the following information was recorded: study setting, year of study, source of funding, patient recruitment details (including number of eligible subjects), inclusion and exclusion criteria, other symptoms, randomisation and allocation concealment method, numbers of participants randomised, blinding (masking) of participants, care providers and outcome assessors, dose and type of intervention, duration of therapy, co-interventions, numbers of patients not followed up, reasons for withdrawals from study protocol (clinical, side-effects, refusal and other), details on side-effects of therapy, and whether intention-to-treat analyses were possible. Data was extracted on the outcomes described previously. Further information was requested from the authors of the single included study (van Adelsberg 2005)
Assessment of risk of bias in included studies
Rias of bias table in Revman was utilised. Aditionally quality assessment of the study included was independently performed by two reviewers (AC, JA). Four components of quality were assessed:
Measures of treatment effect
It was planned that the dichotomous outcome variables of each individual study, relative and absolute risk reductions will be calculated using a modified intention-to-treat analysis. This analysis would have assumed that children not available for outcome assessment have not improved (and probably represents a conservative estimate of effect). An initial qualitative comparison of all the individually analysed studies of all the individually analysed studies to examine whether pooling of results (meta-analysis) would have been reasonable was planned. This would have taken into account differences in study populations, inclusion/exclusion criteria, interventions, outcome assessment, and estimated effect size.
Data synthesis
The results from studies that met the inclusion criteria and reported any of the outcomes of interest would have been included in the subsequent meta-analyses. The summary weighted risk ratio and 95% confidence interval (fixed-effect model) would have been calculated (Cochrane statistical package, RevMan 4.2). For cross-over studies, mean treatment differences would have been calculated from raw data, extracted or imputed and entered as fixed effects generic inverse variance (GIV) outcome, to provide summary weighted differences and 95% confidence intervals. In cross-over trials, only data from the first arm would have been included in meta analysis if data is combined with parallel studies (Elbourne 2002). Numbers needed to treat (NNT) would have been calculated from the pooled OR and its 95% CI applied to a specified baseline risk using an online calculator (Cates 2003). The cough indices would have been assumed to be normally distributed continuous variables so the mean difference in outcomes could be estimated (weighted mean difference). If studies reported outcomes using different measurement scales, the standardised mean difference would have been estimated. Any heterogeneity between the study results would have been described and tested to see if it reached statistical significance using a chi-squared test. The 95% confidence interval estimated using a random-effects model would have been included whenever there are concerns about statistical heterogeneity.
Subgroup analysis and investigation of heterogeneity
An a priori sub-group analysis was planned for children aged less than seven years and seven years and above.
Sensitivity analysis
Sensitivity analyses were planned to assess the impact of the potentially important factors on the overall outcomes: a) study quality; b) study size; c) variation in the inclusion criteria; d) differences in the medications used in the intervention and comparison groups; e) differences in outcome measures; f ) analysis using random effects model; g) analysis by 'treatment received'; h) analysis by 'intention-to-treat'; and See: Characteristics of included studies; Characteristics of excluded studies.
Results of the search
Although the term 'asthma symptoms' which included cough was an inclusion criteria in the first included study (van Adelsberg 2005), it is likely that a number of children would not have fulfilled study criteria of non-specific cough. Data were sought from the corresponding author of the trial but none was received. The study was designed primarily for safety and tolerability of montelukast but analysis included clinical efficacy (see Characteristics of included studies). The study was supported and reported by a commercial interest. The second study (Kooi 2008) included children with cough alone and hence fulfilled inclusion criteria. Raw data provided by the primary author revealed 11 children were in the 'cough only' subgroup of which only 6 (5 in montelukast group and one in placebo group) could be included for this review. 
Risk of bias in included studies
Effects of interventions
One study included 256 randomised subjects (van Adelsberg 2005). There was no difference in all study endpoints between the montelukast and placebo groups. As it was not possible to separate children with non-specific cough from those without, no data have been presented in the MetaView. Cough was not reported as an outcome measure, thus cough-specific related outcomes cannot be described. Clinical adverse events were also not different between groups and no serious adverse events occurred in either group. The second study (Kooi 2008) included in this review had a subgroup that fulfilled the criteria (cough only). Relevant data obtained from the raw results provided by the primary data are displayed in the analysis were but the effect of the intervention could not be estimated as the sample size was too small (n=6).
D I S C U S S I O N
Two randomised controlled trial comparing LTRA with a placebo in children with non-specific cough were identified. These studies were included as the inclusion criteria included children with isolated cough (van Adelsberg 2005, Kooi 2008). The authors included symptoms described as 'asthma symptoms' but it is highly controversial if the diagnosis of asthma can be made in the age group (6-24 months) studied (Strunk 2002). However it is likely that only some of the children in the study would have fulfilled the study criteria. A single cohort study (Kopriva 2004) was also found whereby the time to response was within 3 weeks (mainly within 2 weeks). However this has to interpreted in the context of methodological problems in studies with cough as an outcome measure, specifically the large placebo effect, biased subjective reporting, and period effect (Chang 1999). Given the morbidity associated with chronic cough in children, there is a need for the evaluation of the efficacy of LTRA on non-specific cough in children.
A U T H O R S ' C O N C L U S I O N S Implications for practice
With the lack of evidence, the routine use of LRTA in treating children with non-specific cough cannot be recommended. If LTRA were to be trialled in these children, current cohort data suggest a clinical response (subjective cough severity) usually occurs within two weeks of therapy and definitely within three weeks.
Implications for research
Randomised controlled trials of LTRA to determine the effectiveness in treating children with non-specific cough are clearly needed. Trials should be parallel studies and double blinded, given the known problems in studying cough, specifically the large placebo and time period effects (Chang 1999). Based on cohort data, a short trial of three weeks would suffice. Outcome measures for the clinical studies on cough should be clearly defined using validated subjective data (including quality of life) and supported by objective data if possible. 
A C K N O W L E D G E M E N T S
C H A R A C T E R I S T I C S O F S T U D I E S Characteristics of included studies [ordered by study ID]
Kooi 2008
Methods
Multicenter, randomized, placebo-controlled, double-blind, double-dummy parallel trial ICS or LTRA use was not allowed for a period of 4 weeks preceding the trial. Other exclusion criteria were as follows: use of systemic corticosteroids in the last 2 months; hospitalization for asthma-related symptoms in the last 2 weeks; respiratory disorders other than asthma and poorly controlled systemic diseases. Subsequently, eligible children entered a run-in period of 2 weeks in which the caregivers of the child recorded their child's respiratory symptoms in a diary. Children with symptoms on less than 4 days of the 2-week run-in period or children who used anti-inflammatory medication in this period were excluded at the second visit Quality Assessment: B, A, A, B; high quality score of 2.
Participants
Children were recruited from three outpatient clinics (secondary care) in The Netherlands. Children aged 2-5 years with asthma-like symptoms (wheeze, cough and/or shortness of breath) of sufficient severity to justify the use of prophylactic asthma treatment were eligible for inclusion.63 aged 2-6 years with asthma-like symptoms were included Number of participants in whole study: Fluticasone (n=25), Montelukast (n=18) or placebo (n=20). Mean age (years and SD) in respective groups were 3.8 (71.4) 3.9 (71. 1) and 3.8 (71.3) respectively Number of 'cough only' participants in study: Fluticasone (n=5), Montelukast (n=5) or placebo (n=1)
Interventions Fluticasone (100 ug twice daily via metered dose inhaler and a spacer (Aerochamber)), Montelukast (4mg daily) or placebo (dummy MDI and dummy tablet) for 3 months Outcomes The primary outcome was the daily symptom score (wheeze, cough, shortness of breath) as recorded by caregivers in a symptom diary card which were filled out twice daily during the run-in period and 1 month prior to each follow-up visit. Parents rated their child's night-time and day-time symptoms (cough, wheeze and shortness of breath) on a scale from 0 (no symptoms) to 3 (severe symptoms) each morning and evening. Thus, the total daily symptom score ranged from 0 to 18 Secondary endpoints were rescue medication free days, blood eosinophils and lung function (interrupter technique and forced oscillation technique (FOT)). Data on rescue medication use were derived from the dairy card. The percentage of days on which no rescue medication (salbutamol) was used was calculated. Eosinophils were measured in venous blood at baseline and after 3 months. Lung function was measured using two non-invasive techniques: the interrupter technique and the FOT Adverse events and concomitant medication use were obtained from the diary card Notes Raw data relevant to children with cough and no wheeze were kindly provided by Dr Kooi 
